Fabtech Technologies Ltd Q3 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/bj6z1ja1705kge5q2mtoiyfg.pdf

Key Takeaways


The Q3 Miss: Timing, Not Demand

Aasif Khan: "Activity happened on the ground, but revenue slipped into quarter four."

Order Book & Pipeline

Aasif Khan: "When we speak about medicinal sovereignty, many assume that this is limited to generate facilities. But in reality, the pipeline ahead is much broader and deeper."

Business Model & Competitive Position

Aasif Khan: "So there would not be a company like us which has a very strong design platform, in-house design of oral solids to high-tech vaccines or biosimilars or onco. We have a very beautiful platform of manufacturing critical components that go in the project."

Margins, Cash Flow & Working Capital


Strategic Initiatives

Aasif Khan: "Honestly speaking, we were not very communicative, and we have realised that people... The market has not seen anybody and I don't think so the market has seen anybody like us thus far."

Guidance & Commitments

CommitmentSpecificsTimeline
FY26 revenue and PATRevenue ₹380–400 cr, PAT ₹39–41 crFY26 (guidance intact)
Order book execution₹920+ cr order book executed; major portion in FY27, 30–40% spills to Q1/Q2 FY28Next ~18 months
Order position growth~15% increase in order positionBy end of FY27
Order booking ratioApproximately double the revenue growth targetOngoing
European acquisitionClose acquisition of a European targetNext six months; likely Q1 FY27
TSA Process Equipments exitExit the subsidiaryCurrent financial year
Revenue recognition method evaluationDecision on switching to percentage-completion in some geographiesNext six months to a year
Milestone-based contract transitionNew contract wording becomes effective as old contracts run off12–16 months
Quarterly fluctuationLumpiness expected to persistAt least next two years
FY27 growth target30% year-on-year growthFY27

Key Metrics

MetricQ3 FY26
Revenue₹20.3 cr of material lying at port, delayed and to be billed in Q4; softness purely a timing issue
FY26 revenue guidance₹380–400 cr, reiterated
FY26 PAT guidance₹39–41 cr, reiterated
PAT margin9–11%, expected to remain in this range
Order book₹926 cr as of Jan 31, 2026
Hot lead bank$455 million
Average ticket size$7 million currently; hot lead bank average $7–10 million
Win rate15% in last three months, up from 10–12% historically
In-house manufactured product share30% of supply to a plant, rest from other companies
Marketing and business development expense₹8.5–9 cr annually
Working capital cycle~120 days
Customer advance10–15% advance or full LC; staggered 15%+15% or lump sum 25–30%
FY27 growth target30% year-on-year
Order book execution timeline30–40% of ₹900 cr order book to pass into Q1 or Q2 FY28
Other income₹7 cr, ~10% of total revenue, primarily interest on FDs